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Index (BMI) was signiﬁcantly associated with positive expendi-
tures. Higher BMI was correlated with more positive expendi-
tures. The most appropriate framework for the GLM was the
Gamma distribution. The GLM showed that higher BMI was
associated with greater expenditures. Age, gender, and marital
status (separated and never married) were signiﬁcantly as-
sociated with health care expenditures. Degree of education
(Bachelor and Masters) was also signiﬁcantly related but 
negatively correlated. CONCLUSIONS: Health care expendi-
tures are signiﬁcantly associated with BMI using a gamma dis-
tribution, where age, gender, marital status and education are
also signiﬁcant.
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OBJECTIVES: Obesity has become an important public health
issue because of its link to high rates of avoidable and prema-
ture morbidity and mortality, especially due to its association
with severe cardiovascular diseases and cancer. The objective of
this study is to describe the mortality attributed to obesity in
Spain in 2000 and its associated costs. METHODS: Mortality
associated with obesity was obtained by combining mortality
data for the general population and the PAR (Population Attrib-
utable Risk). Loss of potential productive life years attributable
to obesity was estimated, based on activity rates of population
under 65 years old. The costs associated to premature death were
then obtained by multiplying by mean wage ﬁgures. RESULTS:
18.7% of all the deaths could be attributed to obesity. This mor-
tality was similar in males and females (10.116 vs 11.537). The
life years potentially lost attributable to obesity were 23,510, dis-
tributed as follows: 1015 for DM type 2, 422 for hypertension,
8925 for ischemic heart disease, 3854 for stroke, 61 for
osteoarthritis, 3330 for colorectal cancer, 897 for ovarian cancer,
3649 for breast cancer, 1359 for vesicle cancer. The loss of pro-
ductivity years, based on activity rates for population under 65
years was 12.309, meaning a loss of €294 million. CONCLU-
SIONS: This economic approach to premature death shows how
deep is the impact of obesity on the productivity of our country.
But obesity and its comorbidities increase with age, reaching its
highest prevalence after 65 years old, meaning that the real
impact of obesity in mortality in general is even more signiﬁcant.
Given that abdominal obesity has been proved to be a speciﬁc
risk factor for cardiovascular events, and that its prevalence 
is higher than obesity itself, this analysis could be completed 
by including this parameter, once the data are available in the
literature.
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OBJECTIVES: Rimonabant is a new agent currently seeking
approval by the FDA for the indications of smoking cessation
and treatment of obesity. This study estimates the cost–utility
ratio of rimonabant for the treatment of obesity using data from
two phase–III clinical trials. METHODS: Data from the Rimon-
abant in Obesity (RIO) Europe and RIO Lipids trials, two ran-
domized, double-blinded, placebo-controlled, parallel group,
ﬁxed-dose, multicenter studies, were used to model utilities
gained as increase in quality of life due to a temporary weight
loss during a one-year treatment with rimonabant. In this study,
two separate analyses were conducted: ﬁrst, treatment with
rimonabant 20mg/d plus dietary modiﬁcation versus placebo
plus dietary modiﬁcation and second, comparison of treatment
as above with a hypothetical no intervention group. The second
analysis assumed no reduction in BMI [kg/m2] and zero costs for
the no intervention group. The temporary weight loss for the
treatment and placebo group was calculated assuming a weight
regain to baseline within 3 years after treatment cessation. Costs
included drug acquisition costs (estimated based on costs for
comparable agents), physician ofﬁce visits and dietary counsel-
ing. Efﬁcacy estimates were discounted at 3%. RESULTS:
Reduction in BMI was 2.395 and 0.601 for treatment and
placebo, respectively. In the second analysis, comparison to no
intervention, treatment resulted in a BMI reduction of 3.133.
The incremental cost–utility ratio is $38,884 per QALY com-
paring treatment to placebo and $28,364 per QALY compared
to no intervention. Sensitivity analysis revealed that the results
are sensitive to variations in acquisition costs and sustainability
of weight loss. CONCLUSIONS: Rimonabant is able to increase
quality of life by reducing body weight. This beneﬁt is achieved
at considerable costs; however, the cost–utility ratios are well
below the currently accepted thresholds.
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OBJECTIVE: To predict effects over time on cardiometabolic
risk factors of adding rimonabant to diet and exercise in over-
weight/obese patients. Both weight-dependent and weight-
independent effects of treatment were examined in order to carry
out a Discrete Event Simulation (DES). The DES predicts the
time-dependent course of individual patients’ data according to
treatment. METHODS: Data were taken from 4 RIO trials in
over 6600 overweight/obese patients who received once-daily
rimonabant 20mg (or placebo) on top of diet and exercise. Time-
dependent functions of individual changes in weight, waist cir-
cumference, cholesterol, HDL-cholesterol, triglycerides, HbA1c,
fasting glucose, and blood pressure were required for the DES.
Change over time was analyzed in pooled trial data using a two-
step process: 1) Logistic regressions predicted whether the para-
meter would decrease, and 2) fractional polynomials predicted
change as a function of time and other factors. Random-effects
were included to account for within and between patient vari-
ance. RESULTS: One year of treatment induced cardiometabolic
improvements following a curvilinear course with steep initial
changes and subsequent stabilization after six to nine months.
To properly reﬂect these time-dependent changes, several time
parameters were required in each equation. The degree of change
over time depended on baseline levels and other patient charac-
teristics and on weight changes, but rimonabant 20mg provided
an additional, weight-independent, statistically-signiﬁcant, effect
(OR for worsening 0.36–0.88 depending on outcome consid-
ered). CONCLUSIONS: Multivariate time-dependent analytic
techniques can provide the detailed estimates required for dis-
crete event simulation. Growth curves enable estimation of the
course of each simulated individual over time by providing for
realistic modeling of risks and facilitate probabilistic sensitivity
analyses. These analyses provided a detailed, accurate reﬂection
